Эффективность И Безопасность Местного Применения Циклоспорина А И Депореса В Лечении Заболеваний Сухого Глаза
Обзор
DOI:
https://doi.org/10.61699/cjmps-v2-i1-2-p50-68Ключевые слова:
Cyclosporin A, Restasis, Ikervis, Depores, dry eye diseaseАннотация
Болезнь сухого глаза (БСГ) – многофакторное заболевание, которое приводит к значи тельным осложнениям для зрения. Анализ систематических обзоров лечения БСГ способ ствует выбору наиболее эффективного и безопасного препарата. Данный обзор изучает эффективность применения циклоспорина А и дженерика Depores - офтальмологической эмульсии cyclosporine 0.05% (cyclosporine 0.05%, Deva Pharmaceuticals, Turkey) при лече нии БСГ. Проведён поиск научной информации в базах данных PubMed, PubMed Central, The Cochrane Library, Google Scholar и интернете используя основные ключевые слова: dry eye disease, Cyclosporine A, Ikervis, Restasis, generic cyclosporine 0.05% ophthalmic emulsion, Depores. Также была просмотрена цитированная в научных статьях литература. Исследо вание выявило небольшое количество клинических исследований, оценивающих эффек тивность и безопасность 0,05%-й офтальмологической эмульсии дженерика циклоспори на. Анализ научных статей позволил сделать вывод об эффективности дженерика Restasis – Depores (циклоспорин 0,05%, Deva Pharmaceuticals, Турция) для лечения пациентов с БСГ. Учитывая скудность исследований данного дженерика, желательно изучить результа ты его применения при лечении БСГ в Грузии, которые до сих пор не имели доступа к это му лечению, что поможет улучшить качество жизни с диагнозом «сухого глаза» в Грузии.
Библиографические ссылки
Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluat ion of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112: 1790-4.
Bayrakceken, K, Ugurlu, A. Comparison of the clinical effects of two different doses (0.05% and 0.1%) of topical cyclosporine A in dry eyes with meibomian gland dysfunction. Revista Brasileira de Oftalmologia [online]. 2022, v. 81. https:// doi.org/10.37039/1982.8551. 20220044 3.
Bayraktutar BN, Uçakhan ÖÖ. Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates. Case Rep Ophthalmol. 2016;7(1):135140. Published 2016 Mar 8. doi:10.1159/000444784.
Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11(4):246-258.
Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27(5):520-530. doi:10.5301/EJO.5000952.
Baudouin C, de la Maza MS, Amrane M, et al. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease. Eur J Ophthalmol. 2017;27(6):678-685. doi:10.5301/ ejo.5001002.
Baudouin C, Rolando M, Benitez Del Castillo JM, et al. Reconsidering the central role of mucins in dry eye and ocular surface diseases. Prog Retin Eye Res. 2019;71:6887. doi:10.1016/j.preteyeres.2018.11.007.
Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19(9):1027-1039. doi:10.1080/14656566.2018. https://doi.org/10.1080/14656566.2018.1479742.
Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6(4):468-475. doi:10.1007/BF01973261.
Borel JF. Cyclosporin-A--present experimental status. Transplant Proc. 1981;13(1 Pt 1):344-348.
Branded vs. Generics: You make the call. Ophthalmology Times. December 6, 2018. Available at: https://www.ophthalmologytimes.com/article/branded-vs-generics-youmake-call.
Brignole-Baudouin F, Riancho L, Ismail D, et al. Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease. Invest Ophthalmol Vis Sci. 2017;58(4):2438-2448. doi:10.1167/iovs.15-16555.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438510. doi:10.1016/j.jtos.2017.05.011.
Brzheskiy VV. Sovremennye vozmozhnosti patogeneticheski orientirovannoi terapii sindroma «sukhogo glaza» [Modern possibilities of pathogenetically oriented therapy for dry eye syndrome]. Vestn Oftalmol. 2023;139(2):95-103. doi:10.17116/oftalma202313902195 [in Russian]
Cosar CB, Kilavuzoglu AE, Altıparmak UE, Cenk Çelebi AR. Generic Cyclosporine in the Treatment of Dry Eye Disease. Acıbadem Univ. Sağlık Bilim. Derg. 2022; 13 (2): 241-246 .
Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802-812. doi:10.1016/j.jtos.2017.08.003.
Deshmukh R, Ting DSJ, Elsahn A, Mohammed I, Said DG, Dua HS. Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases. Br J Ophthalmol. 2022;106(8):10871092. doi:10.1136/bjophthalmol-2020-317907.
Dhillion SS, Svarstad H, Amundsen C, Bugge HC. Bioprospecting: effects on environment and development. Ambio. 2002;31(6):491-493. doi:10.1579/0044-7447-31.6.491.
Duran T, Karakuş O, Değim İT, Eser B, Sezigen S, Güney Z, Uluoğlu C. Evaluating of Two Type of Cyclosporine-A Containing Nanosuspension for Ophthalmic Administration. JBACHS. 2021;5:107–116. https://doi.org/10.30621/jbachs.926640.
European Medicines Agency, Generic and Hybrid Medicines. Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/generic-hybridmedicines.
FDA. FDA Approves First Generic of Restasis. 2022 [updated 2022 Feb 2; cited 2022 Sep 22]. Available from: https://www.fda.gov/newsevents/press-announcements/fdaapproves-first-generic-restasis.
FDA. Highlights of prescribing information: RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%. 2013. [cited 2022 Sep 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
Food and Drug Administration. Restasis (cyclosporine ) ophthalmic label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050790s027lbl.pdf
Gouider D, Khallouli A, Maalej A, et al. Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study. Cornea. 2021;40(6):726-732. doi:10.1097/ICO.0000000000002589;
Hirschberg J. The History of Ophthalmology, Vol. 1: Antiquity. Translated by FC Blodi. Bonn, West Germany: Verlag JP Wayenborgh, 1982
Holland EJ, Darvish M, Nichols KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review. Ocul Surf 2019; 17: 412-23.
Holly FJ. Formation and rupture of the tear film. Exp Eye Res. 1973;15(5):515-525. doi:10.1016/0014-4835(73)90064-x.
Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis. Cornea. 2011;30:958–961.
Jerkins GW, Pattar GR, Kannarr SR. A Review of Topical Cyclosporine A Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca. Clin Ophthalmol. 2020;14:481489. Published 2020 Feb 20. doi:10.2147/OPTH.S228070.
Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB. Adenoviral keratoconjunctivitis. Surv Ophthalmol. 2015;60:435–443.
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf 2017; 15: 575-628.
Ikervis summary of product characteristics. Revised 01/2018. Santen SAS. Available at: https://www.medicines.org.uk/emc/product/6937/ smpc/history. Accessed Feb. 14, 2018.
Karpecki PM. The evaluation of dry eye. Review of Optometry. 2015. https://www.reviewofoptometry.com/article/the-evolution-of-dryeye.
Karpecki P, Barghout V, Schenkel B, et al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. BMC Ophthalmol. 2023;23(1):443. Published 2023 Nov 2. doi:10.1186/s12886023-03174-y
Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine.Clin Ophthalmol. 2008;2(4):829-836. doi:10.2147/opth.s1409
Labetoulle M, Leonardi A, Amrane M, et al. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study. Clin Ther. 2018;40(11):1894-1906. doi:10.1016/j.clinthera.2018.09.012
Labetoulle M, Leonardi A, Pisella PJ, Baudouin C. Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers. Ocul Immunol Inflamm. 2023;31(8):17071715. doi:10.1080/09273948.2022.2088566
Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012: 604204
Leonardi A, Van Setten G, Amrane M, et al. Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease: A Multicenter Randomized Trial. European Journal of Ophthalmology. 2016;26(4):287-296. doi:10.5301/ejo.5000779
Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103(1):125-131. doi:10.1136/bjophthalmol-2017-311801
Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivit is. Cornea. 2010;29:638–640.
Levy O, Labbé A, Borderie V, Laroche L, Bouheraoua N. La cyclosporine topique en ophtalmologie : pharmacologie et indications thérapeutiques. J Fr Ophtalmol. 2016;39(3):292-307. doi:10.1016/j. jfo.2015.11.008.
Ling J, Chan BC, Tsang MS, et al. Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine. Front Med (Lausanne). 2022;8:815075. Published 2022 Jan 17. doi:10.3389/ fmed.2021.815075.
Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021;32(4):348-361. doi:10.1097/ ICU.0000000000000768.
Napoli PE, Braghiroli M, Iovino C, Demarinis G, Fossarello M. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops. Drug Des Devel Ther. 2019;13:20012008. Published 2019 Jun 19. doi:10.2147/DDDT.S207453.
Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269-275. doi:10.1016/j.jtos.2017.05.005. de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115-1122. Published 2019 Jul 1. doi:10.2147/OPTH.S184412.
Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A, Erbagci I, Gurler B. Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. BMC Ophthalmol. 2012;18:12–42.
Patel D, Wairkar S. Recent advances in cyclosporine drug delivery. Challenges and opportunities. Drug Delivery and Translational Research 2019; 9: 1067-81.
Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337-342. doi:10.1016/j.ajo.2003.10.036.
Pflugfelder SC, Stern ME. The cornea in keratoconjunctivitis sicca. Exp Eye Res. 2020;201:108295. doi:10.1016/j.exer.2020.108295. van Setten G, Labetoulle M, Baudouin C, Rolando M. Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmol. 2016;94(5):499-506. doi:10.1111/aos.12985.
Shen Lee B, Toyos M, Karpecki P, Schiffbauer J, Sheppard J. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials. Ophthalmol Ther. 2022;11(4):1333-1369. doi:10.1007/s40123-022-00516-9.
Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclo sporine 0.05%. Eye & Contact Lens. 2014; 40: 289-96.
Schulltz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 2014; 6: 37-4.
Singla S, Sarkar L, Joshi M. Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population. A prospective study. Taiwan J Ophthalmol 2019; 9: 173-8.
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf 2017;15:334–365.
Stevenson D, Tauber J, Reis BL. Eff icacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporine a phase 2 study group. Ophthalmology 2000; 107: 967-74.
Tavares Fde P, Fernandes RS, Bernardes TF, Bonfioli AA, Soares EJ. Dry eye disease. Semin Ophthalmol. 2010;25(3):84-93. doi:10.3109/0882 0538.2010.488568.
Valencia-Nieto L, Pinto-Fraga J, Blanco-Vázquez M, et al. Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment. Ophthalmol Ther. 2024;13(5):1197-1210. doi:10.1007/s40123-024-00906-1.
Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15-34. doi:10.1016/s1350-9462(01)00017-9.
Wan KH, Chen LJ, Young AL. Efficacy and safety of topical %0.05 cyclosporine eye drops in the treatment of dry eye syndrome: A systematic review and meta-analysis. Ocul Surf 2015. 13:213-25.
Zghal I, Fekih O, Zgolli HM, Chargui S, Malek I, Nacef L. Cyclosporin A eye drop and subepithelial adenoviral keratoconjunctivitis infiltrates. Tunis Med. 2019;97(5):639-643.
https://ec.europa.eu/health/documents/community-register/2015/20150319131066/anx_131066_en.pdf https://www.santen.com/asia/therapeutic-areas/dryeye/ikervis
https://www.rxreasoner.com/drugs/depores https://prospektus.co/ilac/depores-x-0-1-goz-damlasi-emulsiyon-30-flakon/
